Thanks for the response.
I think EX1 will move around the 50 to 60 bracket before regaining a move higher. Sector tailwinds will help and EX1's unique tech platform is what distinguishes it from the rest, if EV's are to be used economically for drug delivery. They have made no secret of the fact that they are looking for partners and I think that's the left field announcement that will come in next 3 to 6 months which will cause a major re-rate.
Ann: Preclinical Data from Osteoarthritis Animal Study, page-26
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
